Company Overview of APT Therapeutics, Inc.
APT Therapeutics, Inc., a development stage biotechnology drug discovery company, engages in the study of the function and expression of proteins to understand disease mechanisms at the protein, cell, and cell pathway levels. It uses a protein engineering, protein informatics, and cheminformatics software to create base therapeutics and small molecule drugs; and a drug development platform to develop anti-thrombotic therapeutic proteins to be used in stroke, percutaneous coronary intervention, and acute coronary syndrome. The company develops a method to assign biochemical function based on protein evolution, protein structure-function, and enzyme mechanism and catalysis. Its protein informa...
893 North Warson Road
St. Louis, MO 63141
Founded in 2001
Key Executives for APT Therapeutics, Inc.
Chief Executive Officer, President and Director
Founder, Chief Scientific Officer and Director
Co-Founder and Director of Protein Engineering
Head of Legal & Regulatory Affairs
Head of Computational Drug Design
Compensation as of Fiscal Year 2014.
APT Therapeutics, Inc. Key Developments
APT Therapeutics, Inc. Develops Investigational New Drug, APT102, for Heart Attack and Stroke Patients
Oct 2 14
APT Therapeutics, Inc. is developing an investigational new drug, APT102, for heart attack and stroke patients. According to a recent study published in Science Translational Medicine, APT102 maintained optimal blood flow and reduced damage to the heart muscle by 80% in animal model studies of heart attack. Drugs commonly used to prevent blood clots for heart attack and stroke patients carry a risk of serious bleeding events. In contrast, APT102 attenuated bleeding in the study. Two of company's scientists were co-authors of the study, Soon Seog Jeong, PhD, and Ridong Chen, PhD. Dr. Chen is also founder and CEO of the company.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries